Danirixin

Drug Profile

Danirixin

Alternative Names: 1325756; GSK1325756

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Influenza virus infections

Most Recent Events

  • 25 Jan 2017 GlaxoSmithKline plans a phase II trial for Chronic obstructive pulmonary disease (Adjunctive treatment) (PO, Tablet) (NCT03034967)
  • 01 Jan 2017 Phase-II clinical trials in Influenza virus infections (Combination therapy) in USA, Sweden and Spain (IV) (NCT02927431) (EudraCT2016-002512-40)
  • 05 Oct 2016 GlaxoSmithKline plans a phase II trial for Influenza virus infections (Combination therapy) in Sweden, Mexico, Italy, South Korea, Spain, USA, Romania, Russia, Netherlands and France (IV, Infusion) (NCT02927431)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top